BIOMEDevice San Jose is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Medtech Startups Compete at BIOMEDevice San Jose

Silicon Valley is synonymous with startups, so it's no surprise that the region is home to hundreds of businesses innovating in the medtech space. Companies like AtaCor, Medable Sana, and Health ZetaGen Therapeutics based in the region have made it on lists like "25 Medtech Startups You Need to Know."

From apps to wearables, diagnostic tools to minimally invasive surgical devices, innovation in healthcare technology is growing at a compound annual growth rate of 4.5%, on pace to reach a market value of $409.5 billion by 2023. And more specifically, medical startups in 2018 raised $9.5 billion in funding — no small feat considering the path is filled with hurdles like getting approval from insurance companies, government agencies, and other regulatory bodies.

New this year, BIOMEDevice San Jose presents its first Startup Showcase, a product presentation and pitch competition featuring some of the best startups in California. Learn about innovations spanning startup funding stages and hear from the entrepreneurs who are changing the future of healthcare.

Winners of the juried competition will receive a prize package from Informa.

Meet the Competitors:

A&W Engineering Works
A&W develops innovative medical devices. We develop the hardware/software core of the system from front-end sensor to back-end application. This includes the entire analog, digital signal processing, and algorithmic data and control paths through all levels of hardware and software.

Our team has expertise specific to medical device development that runs both deep and wide. We tackle hard to solve medical problems by employing unique development techniques. These deliver fast prototyping and a quick proof of concept, closely followed by final product development. Currently, we are developing exciting new medical devices for pediatrics, breast cancer screening, portable ultrasound imaging, bio-function monitoring, and others. Learn more at http://www.awengworks.com

AddiFab ApS
AddiFab is enabling injection molders to do short-series injection molding with the lead-times, start-up costs and design freedom known from 3D-printing.

Freeform Injection Molding (FIM) - our proprietary platform - exploits the core strengths of Additive Manufacturing to deliver breakthrough launch-time compression at breakthrough costs.

Our aim is to deliver agile hardware manufacturing solutions that help companies leapfrog prototyping and develop next-day products: launch-grade from the first iteration. Learn more at https://www.addifab.com/

Chronus Health
Chronus Health is a medical diagnostic startup building an affordable, point of care blood testing device to accelerate medical decision making in multiple clinical settings. Learn more at https://www.chronushealth.com/

De Oro Devices
De Oro Devices is focused on improving the quality of life for those in need. Our first product, the NexStrideTM, is an assistive device for individuals with Parkinson’s disease who experience freezing of gait. Freezing of gait is one of the most common and most debilitating symptoms of Parkinson’s disease; it takes away people’s independence and greatly decreases quality of life. The NexStride is a small, portable device that attaches to any cane or walker and uses clinically proven sensory cues to help overcome freezing of gait. It is composed of a visual cue (a green laser line) and an audio cue (a metronome). There is currently no effective solution to freezing of gait that is compatible with any cane or walker. De Oro Devices’ mission is to produce a line of products that can help individuals improve their quality of life. Learn more at https://www.deorodevices.com/

HeartBeam, Inc.
Cardiac patients need timely, quality advice as to how to proceed when they experience cardiac disease symptoms. In a heart attack situation, time to medical intervention is of the essence, yet the average delay time from onset of the symptoms to intervention for a heart attack patient is over 3 hours! This delay increases mortality rate by 50%. HeartBeam’s iCardiologist™ addresses this previously unsolved problem. This solution is an entirely new mobile health product offering real-time detection of heart attacks, arrhythmias, and most other cardiac conditions. Some of the breakthrough features of our technology are: 12 lead ECG equivalence with the help of an easy to use, credit card size ECG machine, individualized diagnostic thresholds and 3D diagnostic markers that go beyond human ECG interpretation. iCardiologist has performed superbly in 4 proof of principle studies designed by Harvard Medical School faculty members. It has shown a superior ability to detect a heart attack when compared with 3 experienced cardiologists interpreting the standard 12-lead ECG. iCardiologist benefits the entire healthcare ecosystem. Patients bene?t the most from this life saving technology. Payors will reduce their costs by significantly reducing expenditures for unnecessary chest pain ER visits which are currently estimated at $16B a year. iCardiologist will also compile big data of unprecedented quality enabling an unparalleled preventive and predictive value through AI. HeartBeam’s iCardiologist is a service and the business model is that of SaaS. Learn more at https://www.heartbeam.com/

HiPic, Inc.
HiPic, Inc. was founded by a distinguished biomolecular professor who has received first place award from NIH in 2017 and a product development executive who has launched three product lines, each with over $1B/yr revenue. Learn more at www.hipicinc.com

Koya
At Koya, we are developing the next-generation wearable therapeutic platform which offers compression anytime, anywhere. Compression therapy has wide-ranging applications from treating debilitating diseases such as chronic edema, Chronic Venous Insufficiency (CVI), Congestive Heart Failure (CHF), lymphedema, Deep-Vein Thrombosis (DVT), and post-surgical recovery. Today, the compression and edema market is estimated to be >$4B and growing at 7% CAGR. Existing solutions such as stockings, manual drainage, and Pneumatic Compression Devices (PCDs) are archaic and ineffective. PCDs are bulky, noisy, tethered, and difficult-to-use, yet they remain the standard-of-care for both home-health and hospital care. Our founding team has deep experience in successfully bringing value-based health technologies to market. Koya’s platform is based on advanced materials that allows electro-active compression to be weaved into clothing, making it a truly wearable therapeutic. This platform allows patient-specific patterned compression that is tailored, quiet, portable, and easy-to-wear. We are focused in developing the technology for treating edema with a sensor-based closed-loop system that can address the patient’s chronic needs. The device is IoT-enabled to remotely monitor and enable compliance. Our lean and hyper-efficient operating plan allows us to solve a large and growing unmet need. Learn more at www.koyainc.com

Lume Medical
Lume Medical is a minimally invasive medical device manufacturing company enabling improved vascular access and closure for trans-catheter therapies. We provide an integrated access sheath and closure device based on a "no-touch" surgical predicate that maximizes post-operative vascular patency and leaves no intravascular foreign bodies behind. As transcatheter therapies emerge & thrive, Lume provides a modern option to case closure.

Nasus Medical
Nasus Medical is developing a novel, solution to deliver steroids directly to the target anatomy implicated in Chronic Rhinosinusitis (CRS). This early intervention will enable patients to treat themselves at home, improving their quality of life, and avoiding unnecessary provider visits, medications, and procedures.

CRS affects 36 million patients in the US. The condition accounts for 1-2% of all physician visits and is associated with $7-12 billion in direct US health care costs per year. Nasal steroid sprays are typically prescribed as standard of care, but they are ineffective as they only reach the anterior portion of the nasal cavity. Maximal medical therapy fails in 50% of patients, leaving them with options of taking systemic drugs with serious side effects, having expensive, invasive procedures, or continuing to suffer without sufficient treatment. Learn more at http://nasusmedical.com/

Oncodisc
Oncodisc is a San Francisco Bay Area preclinical startup developing a portfolio of connected vascular access devices.  Our initial product is a connected implantable vascular access port capable of facilitating oncology drug delivery (chemotherapy, immunotherapy, targeted therapy) while also monitoring the health of patients undergoing high risk outpatient therapy.  The 510(k) pathway implant communicates with a smartphone application that handles data and provides critical patient engagement features.  Data analytics solutions will include Artificial Intelligence enabled status alerts identifying patients showing early signs of common complications and targeting them for timely interventions, reducing hospitalizations and lowering costs.  Longitudinal risk scores will provide critical information to clinicians, promoting a personalized approach to individual therapy decisions.  Enterprise level analytics will provide health systems with information to better understand their oncology outcomes and costs, and valuable tools to pharmaceutical and academic researchers developing next generation of cancer treatments.  The Oncodisc management team has rich clinical and medical technology development experience, as well as successful startup exits. Learn more at https://oncodisc.com/

Pulson, Inc.
Pulson was founded by Dr. Jeffery Bleich and has spent the last several years in fundamental research of the phenomena of guided natural counterpulsation. Based on the established medical science of external counterpulsation (ECP) and intra-aortic balloon counterpulsation, Pulson uses the rhythmic contraction of skeletal muscles to provide the "counter-pump", and utilizes a sensor and software to guide the user to counterpulse naturally while walking or running. Learn more at www.counterpace.com